Ghent & Amsterdam, November 8th 2016: Pharmavize, the leading Belgian provider of pharmaceutical development services, and Crystallics, the Dutch solid state research expert, announce today to join forces to deliver streamlined pharmaceutical development services for the pharmaceutical and biotechnology industries.
The two companies merge on their path to establish a leading Contract Development and Manufacturing Organization (CDMO). The combination will provide an integrated service offering consisting of solid state chemistry, analytical & formulation development, drug-product manufacturing and dossier development services. The newly formed group is set to become an international, single-source contractor for pharmaceutical needs that arise during pre-clinical and early-phase drug development.
Harry Christiaens, Chief Executive Officer (CEO) of Pharmavize, stated: “Together we will be best positioned to address early-phase drug development and manufacturing challenges. Pharmavize and Crystallics have a complementary service portfolio. By offering an integrated service level, we will support our customers in accelerating the drug development and drug approval process of their valued pipeline products. This merge strengthens our mission”
“Our vision is to merge specialist service providers with proven track records and established first class reputations into a new company able to serve the pharmaceutical industry with a broad range of high quality services. Pharmavize and Crystallics will form two corner stones of this vision. The customer will be centric in this vision where quality science, research and development, combined with strong customer focus, will drive our growth” adds Gunnar Staaf, CEO of Crystallics.
With a staff of 80 highly qualified employees and some 40 years of combined experience, the company serves a broad customer base from emerging biotech to tier-one pharmaceutical companies in Europe, the United States and Japan. Management and employees, supported by financial investor Mentha Capital, aim to continue the group’s strong organic growth trajectory and will look for further acquisitions to create a leading, integrated CDMO.
Pharmavize is a pharmaceutical development service provider based in Ghent, Belgium. With over 20 years of experience, Pharmavize provides contract services in analytical development, formulation development, drug product manufacturing and assists in CMC regulatory dossier development. The company has a staff of 65 qualified employees and operates an audited 1,600m2 GMP facility, which will be expanded in 2017 with 600 m2 of additional lab facilities. For more information, please visit: www.pharmavize.com or contact us at email@example.com.
Crystallics is a science driven research organization specialized in the identification, characterization and selection of the physical forms of drug substances and is based in Amsterdam, the Netherlands. Crystallics is a pioneer in the field of solid state research and has developed a number of unique and proprietary technologies. These technologies, together with a strong customer focus, make Crystallics a global leader in solid form screening and selection. The company has a staff of 15 qualified employees and operates a 850m2 facility. For more information, please visit: www.crystallics.com or contact us at firstname.lastname@example.org.
About Mentha Capital:
Mentha Capital is an independent private equity firm active in the lower end of the mid-market in the Netherlands and Flanders. Mentha Capital invests in established, mid-sized and profitable companies with clear opportunities for growth along multiple avenues, such as organic growth, expansion in new markets or a buy-and-build approach. Mentha Capital has a significant amount of capital under management from a solid base of wealthy individuals, family offices and institutional investors. For more information, please visit: www.menthacapital.com or contact us at email@example.com.